In recent years, research on immune checkpoint inhibitors, such as programmed cell death protein-1/PD-L1 inhibitors and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors, has become important for identifying key roles in tumor-induced immunosuppression (Van Limbergen et al., 2017). This evidence concerns the gene CD274 and neoplasm.